STAT+: Pharmalittle: We’re reading about Trump’s MFN deals, 340B program controversies, and much more

RegulatoryNegative

AI Analysis

Summary

The Trump administration's most-favored nation drug pricing deals with 16 drugmakers are set to expire after three years, according to SEC filings. The article also discusses 340B program controversies affecting the pharmaceutical industry.

Outcome Details

Most-favored nation (MFN) drug pricing deals expire after three years

Importance:5/10

Sentiment:

-0.30

drug pricingMFN agreements340B programregulatory policyTrump administration

Read the original article

Published by STAT News on March 2, 2026 1:52 PM

Read Original